Ga Young Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ga Young Kim has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Hae Young Chung
Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea
2 shared publications - Hee Jin Jung
Department of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
2 shared publications - Hyung Ryong Moon
Department of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
2 shared publications - Yujin Park
Department of Medicinal Chemistry, New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
2 shared publications - Dahye Yoon
Department of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
1 shared publication - Dongwan Kang
Department of Medicinal Chemistry, New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 39
Alkyl N-Benzylthiocarbamates, the First Copper(II) Ion-Chelating Tyrosinase Inhibitors with a Thiocarbamate Group and ROS-Scavenging Activity, Exhibit Different Inhibitory Activities Depending on the Origin of Tyrosinase
N-Benzylthiocarbamate (NBTC) analogs 1–10 were synthesized as potential Cu2+-chelating tyrosinase inhibitors. Most analogs exhibited strong Cu2+-chelating activity, but none inhibited mushroom tyrosinase (mTYR) activity better than kojic acid (KA). However, owing to their potent cellular TYR inhibitory activity, all analogs, except 8, inhibited melanin formation in B16F10 cells more than KA. Analogs 3, 4, and 9 exhibited stronger antimelanogenic properties than N-phenylthiourea. The TYR inhibitory activity of the analogs of mTYR and B16F10 TYR was probably different because mTYR and mammalian TYR have different structural characteristics. All analogs had a potency to significantly scavenge reactive oxygen species (ROS). Analog 1 was very effective in reducing browning in potato juice. Furthermore, analog 3 inhibited zebrafish larval pigmentation 2000 times more potently than KA and was more effective than N-phenylthiourea. It is believed that their capacity to scavenge ROS amplifies their antimelanogenic effects. Exogenously added CuSO4 attenuated the inhibitions of cellular TYR activity and melanin formation in B16F10 cells caused by analog 9. This result might have been due to the externally added Cu2+ ions forming chelates with 9. The differential TYR inhibitory activity of NBTC analogs appeared to be due to their high sensitivity to interactions with TYRs of different origins.
- 26 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 39
Open AccessAlkyl N-Benzylthiocarbamates, the First Copper(II) Ion-Chelating Tyrosinase Inhibitors with a Thiocarbamate Group and ROS-Scavenging Activity, Exhibit Different Inhibitory Activities Depending on the Origin of Tyrosinase
N-Benzylthiocarbamate (NBTC) analogs 1–10 were synthesized as potential Cu2+-chelating tyrosinase inhibitors. Most analogs exhibited strong Cu2+-chelating activity, but none inhibited mushroom tyrosinase (mTYR) activity better than kojic acid (KA). However, owing to their potent cellular TYR inhibitory activity, all analogs, except 8, inhibited melanin formation in B16F10 cells more than KA. Analogs 3, 4, and 9 exhibited stronger antimelanogenic properties than N-phenylthiourea. The TYR inhibitory activity of the analogs of mTYR and B16F10 TYR was probably different because mTYR and mammalian TYR have different structural characteristics. All analogs had a potency to significantly scavenge reactive oxygen species (ROS). Analog 1 was very effective in reducing browning in potato juice. Furthermore, analog 3 inhibited zebrafish larval pigmentation 2000 times more potently than KA and was more effective than N-phenylthiourea. It is believed that their capacity to scavenge ROS amplifies their antimelanogenic effects. Exogenously added CuSO4 attenuated the inhibitions of cellular TYR activity and melanin formation in B16F10 cells caused by analog 9. This result might have been due to the externally added Cu2+ ions forming chelates with 9. The differential TYR inhibitory activity of NBTC analogs appeared to be due to their high sensitivity to interactions with TYRs of different origins.
- Open Access
Design and Synthesis of (Z)-2-(Benzylamino)-5-benzylidenethiazol-4(5H)-one Derivatives as Tyrosinase Inhibitors and Their Anti-Melanogenic and Antioxidant Effects
In this study, (Z)-2-(benzylamino)-5-benzylidenethiazol-4(5H)-one (BABT) derivatives were designed as tyrosinase inhibitors based on the structure of MHY2081, using a simplified approach. Of the 14 BABT derivatives synthesized, two derivatives ((Z)-2-(benzylamino)-5-(3-hydroxy-4-methoxybenzylidene)thiazol-4(5H)-one [7] and (Z)-2-(benzylamino)-5-(2,4-dihydroxybenzylidene)thiazol-4(5H)-one [8]) showed more potent mushroom tyrosinase inhibitory activities than kojic acid, regardless of the substrate used; in particular, compound 8 was 106-fold more potent than kojic acid when l-tyrosine was used as the substrate. Analysis of Lineweaver–Burk plots for 7 and 8 indicated that they were competitive inhibitors, which was confirmed via in silico docking. In experiments using B16F10 cells, 8 exerted a greater ability to inhibit melanin production than kojic acid, and it inhibited cellular tyrosinase activity in a concentration-dependent manner, indicating that the anti-melanogenic effect of 8 is attributable to its ability to inhibit tyrosinase. In addition, 8 exhibited strong antioxidant activity to scavenge 2,2-diphenyl-1-picrylhydrazyl and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) radicals and peroxynitrite and inhibited the expression of melanogenesis-associated proteins (tyrosinase and microphthalmia-associated transcription factor). These results suggest that BABT derivative 8 is a promising candidate for the treatment of hyperpigmentation-related diseases, owing to its inhibition of melanogenesis-associated protein expression, direct tyrosinase inhibition, and antioxidant activity.
Open AccessDesign and Synthesis of (Z)-2-(Benzylamino)-5-benzylidenethiazol-4(5H)-one Derivatives as Tyrosinase Inhibitors and Their Anti-Melanogenic and Antioxidant Effects
In this study, (Z)-2-(benzylamino)-5-benzylidenethiazol-4(5H)-one (BABT) derivatives were designed as tyrosinase inhibitors based on the structure of MHY2081, using a simplified approach. Of the 14 BABT derivatives synthesized, two derivatives ((Z)-2-(benzylamino)-5-(3-hydroxy-4-methoxybenzylidene)thiazol-4(5H)-one [7] and (Z)-2-(benzylamino)-5-(2,4-dihydroxybenzylidene)thiazol-4(5H)-one [8]) showed more potent mushroom tyrosinase inhibitory activities than kojic acid, regardless of the substrate used; in particular, compound 8 was 106-fold more potent than kojic acid when l-tyrosine was used as the substrate. Analysis of Lineweaver–Burk plots for 7 and 8 indicated that they were competitive inhibitors, which was confirmed via in silico docking. In experiments using B16F10 cells, 8 exerted a greater ability to inhibit melanin production than kojic acid, and it inhibited cellular tyrosinase activity in a concentration-dependent manner, indicating that the anti-melanogenic effect of 8 is attributable to its ability to inhibit tyrosinase. In addition, 8 exhibited strong antioxidant activity to scavenge 2,2-diphenyl-1-picrylhydrazyl and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) radicals and peroxynitrite and inhibited the expression of melanogenesis-associated proteins (tyrosinase and microphthalmia-associated transcription factor). These results suggest that BABT derivative 8 is a promising candidate for the treatment of hyperpigmentation-related diseases, owing to its inhibition of melanogenesis-associated protein expression, direct tyrosinase inhibition, and antioxidant activity.